Logo image of INKT

MINK THERAPEUTICS INC (INKT) Stock Fundamental Analysis

NASDAQ:INKT - Nasdaq - US6036931029 - Common Stock - Currency: USD

8.95  -0.15 (-1.65%)

Fundamental Rating

0

Taking everything into account, INKT scores 0 out of 10 in our fundamental rating. INKT was compared to 571 industry peers in the Biotechnology industry. INKT may be in some trouble as it scores bad on both profitability and health. INKT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INKT has reported negative net income.
In the past year INKT has reported a negative cash flow from operations.
INKT had negative earnings in each of the past 5 years.
In the past 5 years INKT always reported negative operating cash flow.
INKT Yearly Net Income VS EBIT VS OCF VS FCFINKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

INKT has a worse Return On Assets (-186.86%) than 89.82% of its industry peers.
Industry RankSector Rank
ROA -186.86%
ROE N/A
ROIC N/A
ROA(3y)-232.92%
ROA(5y)-574.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INKT Yearly ROA, ROE, ROICINKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INKT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INKT Yearly Profit, Operating, Gross MarginsINKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, INKT has more shares outstanding
INKT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INKT Yearly Shares OutstandingINKT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
INKT Yearly Total Debt VS Total AssetsINKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

INKT has an Altman-Z score of -32.58. This is a bad value and indicates that INKT is not financially healthy and even has some risk of bankruptcy.
INKT's Altman-Z score of -32.58 is on the low side compared to the rest of the industry. INKT is outperformed by 91.61% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -32.58
ROIC/WACCN/A
WACCN/A
INKT Yearly LT Debt VS Equity VS FCFINKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 0.89 indicates that INKT may have some problems paying its short term obligations.
INKT has a worse Current ratio (0.89) than 90.00% of its industry peers.
A Quick Ratio of 0.89 indicates that INKT may have some problems paying its short term obligations.
With a Quick ratio value of 0.89, INKT is not doing good in the industry: 89.29% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.89
Quick Ratio 0.89
INKT Yearly Current Assets VS Current LiabilitesINKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for INKT have decreased strongly by -101.37% in the last year.
EPS 1Y (TTM)-101.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-233.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 41.68% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-464.09%
EPS Next 2Y-104.27%
EPS Next 3Y-63.92%
EPS Next 5Y41.68%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INKT Yearly Revenue VS EstimatesINKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M
INKT Yearly EPS VS EstimatesINKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INKT. In the last year negative earnings were reported.
Also next year INKT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INKT Price Earnings VS Forward Price EarningsINKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INKT Per share dataINKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4

4.3 Compensation for Growth

INKT's earnings are expected to decrease with -63.92% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-104.27%
EPS Next 3Y-63.92%

More info and screens

0

5. Dividend

5.1 Amount

INKT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MINK THERAPEUTICS INC

NASDAQ:INKT (2/28/2025, 8:00:01 PM)

8.95

-0.15 (-1.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-20 2025-03-20/amc
Inst Owners2.09%
Inst Owner Change-4.6%
Ins Owners7.95%
Ins Owner Change0.32%
Market Cap35.44M
Analysts86
Price Target68 (659.78%)
Short Float %N/A
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.05%
Min EPS beat(2)31.37%
Max EPS beat(2)38.73%
EPS beat(4)3
Avg EPS beat(4)24.37%
Min EPS beat(4)-2.3%
Max EPS beat(4)38.73%
EPS beat(8)6
Avg EPS beat(8)18.75%
EPS beat(12)9
Avg EPS beat(12)20.35%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)900%
PT rev (3m)900%
EPS NQ rev (1m)-900%
EPS NQ rev (3m)-900%
EPS NY rev (1m)-900%
EPS NY rev (3m)-1173.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-2.75
Fwd EYN/A
FCF(TTM)-2.74
FCFYN/A
OCF(TTM)-2.74
OCFYN/A
SpS0
BVpS-4.43
TBVpS-4.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -186.86%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-232.92%
ROA(5y)-574.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.67%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.89
Quick Ratio 0.89
Altman-Z -32.58
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)185.6%
Cap/Depr(5y)359.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-101.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-233.33%
EPS Next Y-464.09%
EPS Next 2Y-104.27%
EPS Next 3Y-63.92%
EPS Next 5Y41.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.75%
OCF growth 3YN/A
OCF growth 5YN/A